Sorafenib – Targeted Therapy

Sorafenib is a first-generation multi-kinase inhibitor designed for the targeted therapy of various types of solid tumors. The drug exerts a dual action: it simultaneously inhibits cancer cell proliferation and restricts the tumor's blood supply.

The mechanism of action of sorafenib involves blocking intracellular kinases (C-RAF, BRAF) and receptor tyrosine kinases (VEGFR-2, VEGFR-3, PDGFR-β, KIT, RET). Inhibition of the RAF/MEK/ERK pathways prevents tumor cell division, while targeting VEGFR and PDGFR receptors blocks angiogenesis—the process of new vessel formation. This leads to a slowing of disease progression even in advanced stages. The drug was the first systemic agent to demonstrate efficacy in advanced liver cancer.

Sorafenib is available in oral tablet form and is widely used in global oncological practice as a standard of care for inoperable cancers.

Wikipedia page

Indications

Sorafenib is indicated for the treatment of adult patients with the following pathologies:

Hepatocellular Carcinoma (HCC): therapy for patients with inoperable liver cancer.
Renal Cell Carcinoma (RCC): advanced stages of the disease when prior cytokine therapy has failed or for patients with a poor prognosis.
Differentiated Thyroid Carcinoma (DTC): progressive forms resistant to radioactive iodine therapy.

Dosage and administration

The sorafenib treatment regimen is tailored individually and requires regular blood pressure monitoring.

Standard Dose: 400 mg (two 200 mg tablets) twice daily.
Total Daily Dose: 800 mg.
Administration Rules: tablets should be taken either on an empty stomach or with a low-to-moderate fat meal. They must be swallowed whole with water.
Missed Dose: a double dose should not be taken; resume the schedule with the next dose the following day.
Dose Adjustment: if skin toxicity or hypertension occurs, the physician may reduce the dosage to 400 mg daily or temporarily suspend treatment.

The use of sorafenib is not recommended or prohibited in the following clinical situations:

Hypersensitivity: known allergy to sorafenib or any components of the drug.
Pediatric Use: safety and efficacy in children and adolescents have not been established.
Pregnancy: the drug has teratogenic and embryotoxic effects.
Lactation: breastfeeding must be discontinued during therapy.
Severe Cardiovascular Disease: unstable angina or recent myocardial infarction.

Sorafenib therapy is often accompanied by side effects requiring symptomatic management:

Dermatologic: hand-foot skin reaction (redness, peeling, pain), skin rash, and alopecia (hair thinning).
Cardiovascular: arterial hypertension (increased blood pressure) — requires frequent monitoring.
Gastrointestinal: diarrhea, nausea, vomiting, and stomatitis.
Hematologic: increased risk of bleeding, decreased white blood cell or platelet counts.
General Symptoms: fatigue, joint pain, and weight loss.

Frequently Asked Questions

Sorafenib is a multikinase inhibitor, a targeted therapy that slows down the growth of cancer cells and blocks the development of blood vessels that supply the tumor. It is used to treat hepatocellular carcinoma (liver cancer), advanced renal cell carcinoma (kidney cancer), and differentiated thyroid carcinoma.

Nexavar is the original drug by Bayer. Generics such as Sorafenat (Natco) or Soranib (Cipla) contain the same active ingredient in a 200 mg dosage. Unifarm offers proven Indian analogs that are identical in efficacy but significantly more affordable than the original.

The standard dose is 800 mg daily (two 200 mg tablets twice a day). The drug should be taken on an empty stomach or with a low-to-moderate fat meal. If you plan to have a high-fat meal, take the tablets at least 1 hour before or 2 hours after eating.

This is a common side effect characterized by redness, swelling, or pain on the palms and soles. To prevent this, it is recommended to avoid hot water, wear comfortable shoes, and use moisturizing creams. If significant discomfort occurs, consult your doctor for dose adjustment.

Besides skin reactions, common side effects include diarrhea, fatigue, hypertension, and temporary hair loss. During therapy, it is important to regularly monitor blood pressure and blood counts.

We offer sorafenib from leading Indian manufacturers at competitive prices. The cost of a generic pack is significantly lower than that of the original. Current prices are listed in our catalog.

You can place an order on the Unifarm website via the order form or by calling our contact number. We deliver orders throughout Ukraine. If you need help choosing a specific generic brand, our specialists are ready to answer all your questions.